SynAct Pharma
SynAct Pharma is a clinical-stage Swedish biotechnology company developing resomelagon, an oral selective melanocortin receptor agonist that resolves inflammation rather than suppressing immunity, targeting rheumatoid arthritis, nephrotic syndrome, and viral infections.
- Company typePublic
- Founded2010
- HeadquartersLund, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What SynAct Pharma does
SynAct Pharma AB (publ) is a clinical-stage biotechnology company listed on Nasdaq Stockholm (ticker SYNACT) and Frankfurt (fra:8F8), headquartered in Lund, Sweden with a Danish operating subsidiary in Holte. The company develops selective melanocortin receptor agonists as "resolution therapies" intended to actively stimulate the body's natural inflammation-resolution mechanisms rather than suppress the immune system. Its lead asset, resomelagon (AP1189), is an oral first-in-class selective melanocortin agonist that shifts macrophage phenotypes from pro-inflammatory Type 1-like toward pro-resolving Type 2-like and modulates neutrophil recruitment. The pipeline is being evaluated across inflammatory and autoimmune indications (rheumatoid arthritis, idiopathic membranous nephropathy, polymyalgia rheumatica) and host-directed antiviral therapy (respiratory viral infections, dengue fever, COVID-19), with parallel Phase 2 studies including the 240-patient ADVANCE study in newly diagnosed rheumatoid arthritis (positive topline June 2026), the RESPIRE study in respiratory viral infections, and RESOVIR-2 in dengue fever. A second program, TXP-11, was acquired from TXP Pharma in January 2023 for organ protection and critical care applications.
The company is pre-revenue with no commercialized products. FY2025 operating expenses were SEK 116.5 million and net loss SEK 110.8 million. SynAct's revenue model is built around eventual licensing, partnership, and royalty income from pharmaceutical companies for global co-development and commercialization rights; the company is actively pursuing business development discussions enabled by the ADVANCE data readout. Capital is sourced from equity markets (directed issues, warrant conversions, shareholder-supported placements) and a SEK 40 million credit facility from the largest shareholder, with runway extended into Q3 2027 following a SEK 51.9 million directed share issue in March 2026. The company has secured a US patent on resomelagon providing exclusivity until 2044, supporting the long-term licensing economics of any future deal.
SynAct Pharma firmographics
Firmographics- Name
- SynAct Pharma
- Legal name
- SynAct Pharma AB
- Website
- https://synactpharma.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SynAct Pharma is a clinical-stage Swedish biotechnology company developing resomelagon, an oral selective melanocortin receptor agonist that resolves inflammation rather than suppressing immunity, targeting rheumatoid arthritis, nephrotic syndrome, and viral infections.
- Ownership category
- akta.pro rank
SynAct Pharma industry classification
Industry- Product category
- Clinical-Stage Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where SynAct Pharma is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
SynAct Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotechnology company. Expected to generate revenue through licensing deals, partnerships, and eventual product sales following regulatory approval of resomelagon and other pipeline candidates.
- Strategic Partnerships and Licensing: The company is actively pursuing business development discussions and partnering agreements with pharmaceutical companies for co-development and commercialization rights to resomelagon across different indications and geographies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
SynAct Pharma product offering
Product offeringCore offering
SynAct Pharma is a clinical-stage biotechnology company developing first-in-class oral resolution therapy drugs using selective melanocortin receptor agonists. Its lead compound resomelagon (AP1189) is designed to actively stimulate the body's natural inflammation resolution mechanisms rather than suppress the immune system, targeting rheumatoid arthritis, nephrotic syndrome, and viral infections (respiratory infections, COVID-19, dengue fever). The pipeline also includes TXP-11, a melanocortin agonist program for organ protection and critical care acquired from TXP Pharma.
Product overview
SynAct Pharma is a clinical-stage biotechnology company with a focused pipeline centered on resolution therapy for inflammation. The company's lead product is resomelagon (AP1189), an oral first-in-class selective melanocortin agonist that stimulates the body's natural resolution mechanisms rather than suppressing the immune system. The pipeline includes resomelagon across multiple indications (rheumatoid arthritis, nephrotic syndrome, and viral infections including COVID-19, dengue fever, and respiratory viral infections) in various clinical trial phases, and TXP-11, a separate development program acquired from TXP Pharma focused on melanocortin receptor agonists for organ protection and critical care.
Differentiator
Problem solved
Functional benefit
Products and services
- Resomelagon (AP1189) Oral, first-in-class selective melanocortin receptor agonist (resolution therapy) that induces a shift in macrophage phenotypes from pro-inflammatory Type 1-like to pro-resolving Type 2-like, modulating neutrophil recruitment to resolve inflammation without immunosuppression. Indication targets include rheumatoid arthritis, idiopathic membranous nephropathy, COVID-19, dengue fever, and respiratory viral infections.
- TXP-11 Pre-clinical/clinical melanocortin receptor agonist development program acquired from TXP Pharma, focused on organ protection and critical care applications. Targets hyperinflammatory conditions in intensive care settings.
Quantifiable outcome
- ACR20 response rate of 82% in newly diagnosed RA patients with high hsCRP (>3 mg/L) in subgroup analysis (vs 52% placebo, p<0.05)
- +4 more outcomes
Companies that use SynAct Pharma
Customer profileSegments4 records
Ideal customer profiles2 records
SynAct Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
SynAct Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- TXP PharmacoreAcquisition of Swiss biotech company TXP Pharma in January 2023. SynAct paid SEK 135.99 million through issuing new shares, with additional SEK 55 million potentially payable under predefined conditions. The acquisition enhanced SynAct's pipeline with clinical and pre-clinical assets for developing melanocortin agonists for organ protection and critical care, including TXP-11.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
SynAct Pharma competitors and assessment
Company assessmentDirect peers
- InflaRx N.V. German clinical-stage biotech developing anti-complement therapies (vilobelimab) for inflammatory diseases including hidradenitis suppurativa and critical COVID-19. Closely comparable clinical-stage inflammation biotech with similar size, partnering approach, and focus on non-immunosuppressive anti-inflammatory mechanisms.
- Travere Therapeutics: US biotech developing sparsentan (Filspari) for IgA nephropathy and focal segmental glomerulosclerosis. Directly comparable on the nephrotic syndrome indication that SynAct's iMN program targets, and represents a competitive benchmark in the rare kidney disease space.
- Calliditas Therapeutics: Swedish clinical-stage biotech focused on nephrology/immunology with lead asset Nefecon (Tarpeyo) for IgA nephropathy. Most directly comparable to SynAct as a Nordic small-cap biotech developing innovative therapies for nephrotic/immunological kidney diseases, listed on Nasdaq Stockholm with similar partnership-oriented commercialization model.
Broad incumbents
- Galapagos NV: Belgian-Dutch biotech with established RA franchise (filgotinib, Jyseleca) and broader inflammation/immunology pipeline. Comparable as a European inflammation-focused biotech targeting RA, with deeper resources but similar clinical-development trajectory and partnering model.
- ChemoCentryx (Amgen): Acquired by Amgen in 2022 for $3.7B, ChemoCentryx developed Tavalisse for inflammatory/autoimmune diseases. Comparable as a clinical-stage inflammation biotech that ultimately achieved a successful strategic exit, providing a relevant valuation benchmark for SynAct's potential acquisition outcome.
Emerging players
- Aclaris Therapeutics: US clinical-stage biotech developing novel immuno-inflammatory therapies (zunsemetinib/ATI-450) for autoimmune diseases. Comparable as a small-cap inflammation biotech with novel mechanisms and BD-driven commercialization approach, though focused on different specific indications.
- AbCellera Biologics: Canadian antibody discovery platform that has partnered with multiple pharma companies including Eli Lilly for immunology targets. Comparable as a small-cap clinical/biotech enabler with partnership-driven revenue model, though broader in therapeutic area and platform-based rather than single asset.
- Landos Biopharma: Clinical-stage biotech developing first-in-class oral therapeutics for autoimmune diseases (ulcerative colitis, Crohn's). Comparable as a small-cap inflammation biotech with novel oral mechanism, single-asset focus, and similar partnering/BD commercialization model.
Market position
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
SynAct Pharma social profiles
Digital presenceSynAct Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
SynAct Pharma leadership team
Management profileNumber of profiles
Profiles7 records
SynAct Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
SynAct Pharma funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SynAct Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SynAct Pharma
What does SynAct Pharma do?
SynAct Pharma is a clinical-stage biotechnology company developing first-in-class oral resolution therapy drugs using selective melanocortin receptor agonists. Its lead compound resomelagon (AP1189) is designed to actively stimulate the body's natural inflammation resolution mechanisms rather than suppress the immune system, targeting rheumatoid arthritis, nephrotic syndrome, and viral infections (respiratory infections, COVID-19, dengue fever). The pipeline also includes TXP-11, a melanocortin agonist program for organ protection and critical care acquired from TXP Pharma.
Is SynAct Pharma a public or private company?
SynAct Pharma is a public company. It is classified as public and is currently operating.
When was SynAct Pharma founded?
SynAct Pharma was founded in 2010. It employs 1 to 10 people.
Where is SynAct Pharma based?
SynAct Pharma is headquartered in Lund, Sweden, in the Europe region.
How does SynAct Pharma make money?
Two revenue lines are on record. Pharmaceutical Product Revenue is the primary driver. The others are strategic Partnerships and Licensing.
Who are SynAct Pharma's main competitors?
Direct peers on record are InflaRx N.V., Travere Therapeutics and Calliditas Therapeutics. Broad incumbents are Galapagos NV and ChemoCentryx (Amgen). Emerging players are Aclaris Therapeutics, AbCellera Biologics and Landos Biopharma.
Does SynAct Pharma have an API?
No public API is recorded for SynAct Pharma.
What industry is SynAct Pharma in?
SynAct Pharma's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.